Nora Pashayan, MD, PhD; Steve Morris, PhD; Fiona J. Gilbert, MBChB, FRCR; et al.
open access
has audio
JAMA Oncol. 2018;4(11):1504-1510. doi:10.1001/jamaoncol.2018.1901
This cost-effectiveness study uses a life-table model of a hypothetical cohort of 364 500 women to evaluate the cost-effectiveness and benefit to harm ratio of risk-stratified screening for breast cancer.
-
Audio Author Interview:
Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening
Monica Morrow, MD; Reshma Jagsi, MD, DPhil; M. Chandler McLeod, PhD; et al.
free access
JAMA Oncol. 2018;4(11):1511-1516. doi:10.1001/jamaoncol.2018.1908
This survey study examines the propensity of surgeons to use axillary lymph node biopsy alone for axillary management in women with early-stage breast cancer undergoing breast-conserving surgery.
Robert L. Dood, MD, MSCE; Yang Zhao, MS; Shannon D. Armbruster, MD, MPH; et al.
free access
JAMA Oncol. 2018;4(11):1519-1526. doi:10.1001/jamaoncol.2018.2761
This cohort study uses Surveillance, Epidemiology, and End Results data to determine high- and low-risk periods for 68 cancer types that could define when survivorship care might best be overseen by oncologists and when to transition to primary care physicians.
Geoffrey R. Oxnard, MD; Yuebi Hu, AB; Kathryn F. Mileham, MD; et al.
free access
JAMA Oncol. 2018;4(11):1527-1534. doi:10.1001/jamaoncol.2018.2969
This cohort study examines mechanisms of acquired resistance to osimertinib in patients with non–small cell lung cancer and the associated clinical implications.
Charles C. Peyton, MD; Dominic Tang, MD; Richard R. Reich, PhD; et al.
free access
JAMA Oncol. 2018;4(11):1535-1542. doi:10.1001/jamaoncol.2018.3542
This cross-sectional analysis compares downstaging, responses, and survival outcomes in patients with muscle-invasive bladder cancer treated with cystectomy who underwent neoadjuvant chemotherapy with gemcitabine with cisplatin, gemcitabine with carboplatin, or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin.
Roberto Ferrara, MD; Laura Mezquita, MD, PhD; Matthieu Texier, MSc; et al.
free access
has audio
JAMA Oncol. 2018;4(11):1543-1552. doi:10.1001/jamaoncol.2018.3676
This multicenter cohort study investigates whether hyperprogressive disease is observed in patients with advanced non–small cell lung cancer treated with programmed cell death 1 and programmed cell death ligand 1 inhibitors compared with single-agent chemotherapy.
-
Audio Author Interview:
Hyperprogressive Disease in Patients With Advanced NSCLC Treated With PD-1/PD-L1 Inhibitors
Global Burden of Disease Cancer Collaboration
open access
JAMA Oncol. 2018;4(11):1553-1568. doi:10.1001/jamaoncol.2018.2706
This systematic analysis evaluates the cancer burden over time at the global and national levels measured in incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years.
Baohui Han, MD; Kai Li, MD; Qiming Wang, MD; et al.
open access
JAMA Oncol. 2018;4(11):1569-1575. doi:10.1001/jamaoncol.2018.3039
This randomized clinical trial examines the efficacy of anlotinib compared with placebo as a third-line or further therapy on overall survival of adult patients with advanced non–small cell lung cancer.
John Maret-Ouda, MD, PhD; Karl Wahlin, MSc, PhD; Miia Artama, PhD; et al.
free access
JAMA Oncol. 2018;4(11):1576-1582. doi:10.1001/jamaoncol.2018.3054
This cohort study of patients from the 5 Nordic countries examines whether gastroesophageal antireflux surgery is associated with decreased risk of esophageal adenocarcinoma and whether surgically and medically treated patients experience different outcomes.
The Premenopausal Breast Cancer Collaborative Group
open access
online only
JAMA Oncol. 2018;4(11):e181771. doi:10.1001/jamaoncol.2018.1771
This pooled analysis of individual patient data investigates the association of body mass index with subsequent breast cancer risk, in particular by age, attained age, risk factors for breast cancer, and tumor characteristics, in premenopausal women.
Robert Scragg, MBBS, PhD; Kay-Tee Khaw, MBBChir, MSc; Les Toop, MBChB, MD; et al.
free access
online only
JAMA Oncol. 2018;4(11):e182178. doi:10.1001/jamaoncol.2018.2178
This post hoc analysis of the Vitamin D Assessment randomized clinical trial assesses the association of monthly high-dose vitamin D supplementation vs placebo on cancer risk among New Zealand adults.